Premium
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
Author(s) -
Angelopoulou Maria K.,
Vassilakopoulos Theodoros P.,
Batsis Ioannis,
Sakellari Ioanna,
Gkirkas Konstantinos,
Pappa Vasiliki,
Giannoulia Panagiota,
Apostolidis Ioannis,
Apostolopoulos Christos,
Roussou Paraskevi,
Panayiotidis Panayiotis,
Dimou Maria,
Kyrtsonis MarieChristine,
Palassopoulou Maria,
Vassilopoulos Georgios,
Moschogiannis Maria,
Kalpadakis Christina,
Margaritis Dimitrios,
Spyridonidis Alexander,
Michalis Eurydiki,
Anargyrou Konstantinos,
Repousis Panagiotis,
Hatzimichael Eleutheria,
Bousiou Zoi,
Poulakidas Elias,
Grentzelias Dimitrios,
Harhalakis Nikolaos,
Pangalis Gerassimos A.,
Anagnostopoulos Achilles,
Tsirigotis Panagiotis
Publication year - 2018
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2383
Subject(s) - brentuximab vedotin , medicine , refractory (planetary science) , transplantation , autologous stem cell transplantation , lymphoma , gastroenterology , progressive disease , surgery , salvage therapy , progression free survival , oncology , chemotherapy , hodgkin lymphoma , physics , astrobiology
This retrospective study aimed to describe the Hellenic experience on the use of brentuximab vedotin (BV) in relapsed/refractory (R/R) Hodgkin lymphoma (HL) given within its indication. From June 2011 to April 2015, ninety‐five patients with R/R HL, who received BV in 20 centers from Greece, were analyzed. Their median age was 33 years, and 62% were males. Sixty‐seven patients received BV after autologous stem cell transplantation failure, whereas 28 patients were treated with BV without a prior autologous stem cell transplantation, due to advanced age/comorbidities or chemorefractory disease. The median number of prior treatments was 4 and 44% of the patients were refractory to their most recent therapy. The median number of BV cycles was 8 (range, 2‐16), and the median time to best response was the fourth cycle. Fifty‐seven patients achieved an objective response: twenty‐two (23%), a complete response (CR), and 35 patients (37%), a partial, for an overall response rate of 60%. Twelve patients (13%) had stable disease, and the remaining twenty‐six (27%) had progressive disease as their best response. At a median follow‐up of 11.5 months, median progression‐free survival and overall survival were 8 and 26.5 months, respectively. Multivariate analysis showed that chemosensitivity to treatment administered before BV was associated with a significantly increased probability of achieving response to BV ( P = .005). Bulky disease ( P = .01) and response to BV ( P <.001) were significant for progression‐free survival, while refractoriness to most recent treatment ( P = .04), bulky disease ( P = .005), and B‐symptoms ( P = .001) were unfavorable factors for overall survival. Among the 22 CRs, 5 remain in CR with no further treatment after BV at a median follow‐up of 13 months. In conclusion, our data indicate that BV is an effective treatment for R/R HL patients even outside clinical trials. Whether BV can cure a fraction of patients remains to be seen.